Abstract
The benzothiazole aniline (BTA) conjugated with monoamine-monoamide (MAMA) was synthesized and then labeled with (99m)Tc. Its corresponding rhenium analogue was synthesized, and the fluorescent staining was performed in brain sections of both Tg mouse and Alzheimer's disease (AD) patient. The fluorescent rhenium complex Re-MAMA-BTA selectively bound to the amyloid aggregates in the brain sections of both APP Tg mouse and AD patient. The analogous (99m)Tc-MAMA-BTA complex could enter the normal mouse brain with high initial uptake. These results are encouraging for further exploration of their derivatives as imaging agents for Abeta plaques in the brain.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Alzheimer Disease / diagnostic imaging*
-
Alzheimer Disease / metabolism
-
Amides / chemistry
-
Amines / chemistry
-
Amyloid beta-Peptides / analysis*
-
Amyloid beta-Peptides / metabolism
-
Animals
-
Benzothiazoles / chemistry
-
Blood-Brain Barrier / metabolism
-
Brain / diagnostic imaging*
-
Brain / metabolism
-
Humans
-
Isotope Labeling
-
Male
-
Mice
-
Microscopy, Fluorescence
-
Middle Aged
-
Organotechnetium Compounds / chemical synthesis*
-
Organotechnetium Compounds / pharmacokinetics
-
Radionuclide Imaging
-
Radiopharmaceuticals / chemical synthesis*
-
Radiopharmaceuticals / pharmacokinetics
-
Rhenium / chemistry
-
Technetium Compounds / chemistry
-
Tissue Distribution
Substances
-
2-(4-aminophenyl)benzothiazole
-
99mTc-MAMA-BTA
-
Amides
-
Amines
-
Amyloid beta-Peptides
-
Benzothiazoles
-
Organotechnetium Compounds
-
Radiopharmaceuticals
-
Technetium Compounds
-
Rhenium